Ildong Holdings Co., Ltd. Stock

Equities

A000230

KR7000230003

Pharmaceuticals

End-of-day quote Korea S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
8,700 KRW +0.12% Intraday chart for Ildong Holdings Co., Ltd. +3.08% -17.30%
Sales 2022 676B 490M Sales 2023 638B 464M Capitalization 119B 86.24M
Net income 2022 -102B -74.31M Net income 2023 -59.59B -43.26M EV / Sales 2022 0.61 x
Net Debt 2022 182B 132M Net Debt 2023 242B 176M EV / Sales 2023 0.57 x
P/E ratio 2022
-2.11 x
P/E ratio 2023
-1.99 x
Employees -
Yield 2022
0.5%
Yield 2023
0.95%
Free-Float 51.25%
More Fundamentals * Assessed data
Dynamic Chart
Ildong Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Ildong Holdings Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Ildong Holdings Co., Ltd.(KOSE:A000230) dropped from S&P Global BMI Index CI
Ildong Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Idience Co., Ltd announced that it has received KRW 14.9949886 billion in funding from Ildong Holdings Co., Ltd. CI
Idience Co., Ltd announced that it expects to receive KRW 14.9949886 billion in funding from Ildong Holdings Co., Ltd. CI
Ildong Holdings Co., Ltd. announced that it has received KRW 30 billion in funding CI
Ildong Holdings Co., Ltd. announced that it expects to receive KRW 30 billion in funding CI
Ildong Holdings Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Ildong Holdings Co., Ltd.(KOSE:A000230) added to S&P Global BMI Index CI
Ildong Holdings Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Twist Bioscience, Ildong Pharmaceutical Partner to Discover Antibodies for Immuno-Oncology MT
Idience Co., Ltd announced that it expects to receive KRW 15.0050118 billion in funding from Ildong Holdings Co., Ltd., Yuanta Investment, Kiwoom Securities Co., Ltd., Investment Arm and other investors CI
Ildong Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Ildong Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
More news
1 day+0.12%
1 week+3.08%
Current month-5.84%
1 month-8.81%
3 months-8.13%
6 months-16.02%
Current year-17.30%
More quotes
1 week
8 450.00
Extreme 8450
9 000.00
1 month
8 270.00
Extreme 8270
9 470.00
Current year
8 270.00
Extreme 8270
10 620.00
1 year
8 200.00
Extreme 8200
16 790.00
3 years
8 200.00
Extreme 8200
59 200.00
5 years
6 210.00
Extreme 6210
59 200.00
10 years
6 210.00
Extreme 6210
59 200.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 81 03-05-29
Director/Board Member 56 08-05-29
Director/Board Member 73 13-03-14
Members of the board TitleAgeSince
Director/Board Member 56 08-05-29
Chief Executive Officer 81 03-05-29
Director/Board Member 59 -
More insiders
Date Price Change Volume
24-04-25 8,700 +0.12% 6 735
24-04-25 8,690 -0.11% 9,034
24-04-24 8,700 +0.12% 7,596
24-04-23 8,690 +0.70% 5,231
24-04-22 8,630 +0.23% 8,098

End-of-day quote Korea S.E., April 25, 2024

More quotes
Ildong Holdings Co., Ltd., formerly Ildong Pharmaceuticals Co., Ltd., is a Korea-based company engaged in the manufacture of pharmaceuticals. The Company’s products mainly include general drugs and specialty drugs, such as vitamin supplements, digestive medications, vascular medications, probiotics, topical applications, anti-histamines, antipyretics, analgesics, respiratory medications, endocrine medications, psychoneurological medications, dermatological medications, urologic medications, antibiotics and others. It also provides raw materials, such as synthesises, probiotics and others. In addition, through its subsidiaries, it engages in the advertising agency, medical equipment distribution, software development, food processing and other businesses.
More about the company
  1. Stock Market
  2. Equities
  3. A000230 Stock